Drugs / Rebastinib
Rebastinib
also known as
DCC-2036 · DCC-2036 FREE BASE · DP-1919 · DP-1919.TO · Dp-1919.to, dcc-2036 · Rebastinib tosilate · REBASTINIB TOSYLATE
Small molecule targets ABL1, KDR, LYN via inhibition
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02824575 | Jul 2016 → Dec 2021 | Her2-receptor negative breast cancer, breast adenocarcinoma | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT00827138 | Mar 2009 → Jan 2013 | chronic myeloid leukemia | Deciphera Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03717415 | Jan 2019 → May 2022 | — | Deciphera Pharmaceuticals, LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT03601897 | Oct 2018 → May 2022 | — | Deciphera Pharmaceuticals, LLC | Terminated | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rebastinib | “Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.” PMID 27927766 ↗ Dec 2016 |
| Known as | DCC-2036 | “A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors” NCT03717415 ↗ |
| Known as | DCC-2036 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Known as | DP-1919 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Known as | DP-1919.TO | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Known as | Dp-1919.to, dcc-2036 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Known as | Rebastinib tosilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Known as | REBASTINIB TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738757 ↗ |
| Action | Inhibit | “DCC-2036 is a potent broad spectrum inhibitor of BCR-ABL kinase.” NCT00827138 ↗1“Tyrosine-protein kinase ABL inhibitor” CHEMBL1738757 ↗ |
| Modality | Small molecule | — CHEMBL1738757 ↗ |
| Route | Oral | “150 mg BID tablets, continuous dosing of 28 day cycles” NCT00827138 ↗ |
| Target | ABL1 | “Tyrosine-protein kinase ABL inhibitor” CHEMBL1738757 ↗ |
| Target | KDR | “DCC-2036 also inhibits FLT3-ITD, TIE2, KDR, LYN and TRKA kinases.” NCT00827138 ↗ |
| Target | LYN | “DCC-2036 also inhibits FLT3-ITD, TIE2, KDR, LYN and TRKA kinases.” NCT00827138 ↗ |